Nu-Med Plus (NUMD) EBT Growth (3y) (2015 - 2025)
Nu-Med Plus (NUMD) EBT Growth (3y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 199.71 Bn | 194.11 Bn | 7.27 Bn | -2.34% |
| 2 | Stryker | 129.50 Bn | 126.03 Bn | 4.50 Bn | 20.27% |
| 3 | Medtronic | 119.85 Bn | 110.63 Bn | 6.41 Bn | 5.75% |
| 4 | Boston Scientific | 73.79 Bn | 73.25 Bn | 3.85 Bn | 35.51% |
| 5 | Edwards Lifesciences | 52.68 Bn | 48.42 Bn | 1.35 Bn | 23.63% |
| 6 | Dexcom | 34.58 Bn | 32.64 Bn | 830.00 Mn | 25.85% |
| 7 | GE HealthCare Technologies | 34.14 Bn | 32.03 Bn | 2.18 Bn | 6.73% |
| 8 | Koninklijke Philips | 26.45 Bn | 23.13 Bn | 4.55 Bn | 89.20% |
| 9 | Steris | 23.23 Bn | 22.74 Bn | 684.20 Mn | 17.92% |
| 10 | Nu-Med Plus | 1.70 Mn | 1.69 Mn | - | 41.09% |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -31.93% |
| Sep 30, 2025 | 40.93% |
| Jun 30, 2025 | 41.43% |
| Mar 31, 2025 | 30.61% |
| Dec 31, 2024 | 83.10% |
| Sep 30, 2024 | 45.96% |
| Jun 30, 2024 | 59.06% |
| Mar 31, 2024 | 60.60% |
| Dec 31, 2023 | 51.87% |
| Sep 30, 2023 | 66.93% |
| Jun 30, 2023 | 70.09% |
| Mar 31, 2023 | 43.62% |
| Dec 31, 2022 | 30.06% |
| Sep 30, 2022 | 27.22% |
| Jun 30, 2022 | 37.63% |
| Mar 31, 2022 | 48.34% |
| Dec 31, 2021 | -83.51% |
| Sep 30, 2021 | 38.84% |
| Jun 30, 2021 | -15.42% |
| Mar 31, 2021 | -37.39% |